48 小时经皮丁丙诺啡导入延长释放丁丙诺啡。
48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine.
机构信息
From the Integrated Psychiatry, Pain, and Addiction Service, Vancouver General Hospital, Vancouver, British Columbia, Canada (PA, JSHW, NM, MJI); Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada (PA, NM); Addictions and Concurrent Disorders Research Group, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada (JSHW, RMK); BC Mental Health & Substance Use Services, Provincial Health Services Authority, British Columbia, Canada (NM); Substance Use Response and Facilitation Service, BC Children's Hospital, Provincial Health Services Authority, British Columbia, Canada (MJI); Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, British Columbia, Canada (NP); Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (NP); British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada (AA, MH, RB, JSGM); Pharmacokinetics Modeling and Simulation Laboratory, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (ST, ARM); Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (MH); School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (RB); and Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (JSGM).
出版信息
J Addict Med. 2024;18(1):82-85. doi: 10.1097/ADM.0000000000001231. Epub 2023 Oct 17.
Buprenorphine extended-release (BUP-XR) provides sustained delivery of buprenorphine to control withdrawal and craving symptoms in the form of a monthly injectable and has been shown to improve health outcomes in patients with opioid use disorder. It is recommended that patients are stabilized with a transmucosal buprenorphine product, for at least 7 days per the product monograph; however, clinically, this timeline may be expedited. We report a case of a hospitalized patient with unregulated fentanyl use who underwent a successful transdermal buprenorphine induction for 48 hours to initiate BUP-XR with minimal levels of withdrawal and without precipitating opioid withdrawal. The approach described could provide a practical, patient-centered, accelerated induction strategy that, once independently validated, could considerably facilitate the use of BUP-XR.
丁丙诺啡缓释剂（BUP-XR）以每月注射一次的形式提供丁丙诺啡的持续释放，以控制戒断和渴望症状，已被证明能改善阿片类药物使用障碍患者的健康结果。根据产品说明书，建议患者先用经粘膜丁丙诺啡产品稳定至少 7 天；然而，在临床上，这个时间线可能会加快。我们报告了一例患有未经管制的芬太尼使用的住院患者，他成功地进行了 48 小时的经皮丁丙诺啡诱导，以开始使用 BUP-XR，戒断症状最小，且没有引发阿片类药物戒断。所描述的方法可以提供一种实用的、以患者为中心的加速诱导策略，一旦独立验证，将极大地促进 BUP-XR 的使用。
Zotero 插件